The sector is a little weak this morning, which is to be expected but not nearly as weak as I thought it would be going into the open. There has been some negative news (or mixed depending on your view) and I figured this would weigh more heavily on the group. It is obviously still […]
July 21 Biotech Update
The sector was green again yesterday and this morning but it does not seem to be a broad based move. The small caps appear to be underperforming and among the large caps it seems isolated to CELG with AMGN and GILD being relatively weak. This narrowing of the move tells me that we are much […]
July 20 Biotech Update
There is some news this morning but nothing that in and of itself is likely to move the sector. On the other hand, the news has generally been positive, so there is nothing to change the momentum to the upside. It is nice to see a week begin without a major macro discussion. Perhaps this […]
July 17 Biotech Update
I leave town and the sector runs to new all-time highs and I come back and there is a pullback. Perhaps the market is trying to tell me something. It is not surprising to see a pause even a pullback but I also think people were underinvested expecting a deeper sell-off, so I am not […]
TRIL – Preparing For The Next Move Upward
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat” signal to macrophages. High expression of CD47 by tumor cells has been correlated with more aggressive disease and poor survival. SIRPαFc is initially being developed […]
July 9 Biotech Update
It is a new day and apparently a new market with everything now OK. Clearly chop is the order of the summer (as is amnesia with the market having almost no memory day to day). As always it matters less how we start and more how we end but given the lack of any real […]
July 8 Biotech Update
We end one macro crisis and head directly into another. China, however, is more important than Greece so this makes a little more sense but even this selling is likely overdone (but that does not mean it’s over). I am not sure there is any real biotech news, so I want to highlight one discussion […]
Catalyst Watch – Vol. 3, Edition 9 (7/8/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CNAT: The company […]
July 7 Biotech Update
There is a little more news today but still relatively quiet. The market seems to be looking for a direction but the sector seems to be outperforming to the upside. Yesterday was certainly better than expected but it also did not end in an exceptionally bullish manner. That is why I still think the market […]
July 6 Biotech Update
A pretty quiet start to the week (at least in terms of bio news). Obviously we have all the Greek drama but despite fears of the worst, the opening was not too bad and stocks seem to be rallying with bios taking the lead. While it is way too early to read into the price […]
July 3 Biotech Update
This is the last note before the fourth and I wanted to spend time going into a new therapeutic space and highlight a new company (well, it is new to me but has already had a good run this year). I also wanted to wrap up the discussion from yesterday as the trading action is […]
July 1 Biotech Update
I am back from vacation and ready to get back into the sector. I planned on talking about the CGPR space today but I will push that back until tomorrow (but ALDR is on my radar to buy so do not be surprised if I start a position between now and tomorrow’s note but it […]
June 18 Biotech Update
The summer is seasonally weak, especially after the EHA and ASCO- right? I am not sure of the exact catalyst for the move today but it is certainly moving the sector higher (with the broader market as well). There was not a lot of news, so perhaps this is simply the end of the buyer […]
June 17 Biotech Update
Market doing a little better but biotechs seemed to take yesterday off despite the broader rally. The sector seems to be more positive today (there were certainly bright spots yesterday but in general the sector appeared to underperform). We are helped by some M&A, which goes with the speculation that developed yesterday. Again, the summer […]
June 16 Biotech Update
The market is quite resilient. While we did not get a full reversal yesterday, the market came back and biotechs seemed to outperform. This morning is off to a good start as the late day move is getting some follow through (but was quickly squashed as we seem once again bound in a range). Of […]
June 15 Biotech Update
It is a macro world and we are just living in it. Sunday night we should have known this was going to be a bad start to the week with the two themes being Greece and the biotech bubble. Both themes are pretty trite but they are both negative headline risks. Outside of the headline […]
The Reality for Mannkind
Mannkind, the maker of the inhaled insulin product Afrezza, is the 11th best performing biotech stock according to Finviz in the last month, up 62%. That performance is in line with several big ASCO winners such as Oncothyreon, Ignyta and Immunogen. Also on the list is DMD company Sarepta, which has new hope for an […]
June 12 Biotech Update
The market is not happy this morning and it is not immediately clear as to the “cause.” This is taking the sector down, especially some of the recent fliers. The summer is generally not a great time for the sector and we have had a lull in M&A, so it could be time for a […]
June 10 Biotech Update
This is sort of a different start to the day with the market off to a good start but biotechs the obvious laggard. The sector had been one of the relative bright spots but now that the market is recovering, they are lagging. This seems more news related (discussed below) and we need to see […]
June 9 Biotech Update
The market continues to sell off with biotechs seemingly able to levitate but still weak this morning. Either the market is going to reverse in the near term or it is going to take biotech down with it in a large move lower. At least in the very near term, I think the market is […]
